The Coriell personalized medicine collaborative pharmacogenomics appraisal, evidence scoring and interpretation system
The Coriell personalized medicine collaborative pharmacogenomics appraisal, evidence scoring and interpretation system
复制标题
DOI：
10.1186/gm499
复制
发表时间：
2013-10-18
期刊：
影响因子：
12.3
通讯作者：
Christman, Michael F.
中科院分区：
文献类型：
--
作者：
Gharani, Neda;Keller, Margaret A.;Christman, Michael F.
在临床护理中实施药物基因组学（PGx）可以提高药物疗效，减少药物不良反应。然而，在临床实践中采用PGx检测存在滞后。这在一定程度上是由于缺乏将已发表的临床和科学数据转化为具有明确治疗建议的标准化诊断测试的严格系统。本文介绍了作为科里尔个性化医学合作研究的一部分开发的药物基因组学评估、证据评分和解释系统（PhAESIS）及其在七种常用处方药中的应用。
Implementation of pharmacogenomics (PGx) in clinical care can lead to improved drug efficacy and reduced adverse drug reactions. However, there has been a lag in adoption of PGx tests in clinical practice. This is due in part to a paucity of rigorous systems for translating published clinical and scientific data into standardized diagnostic tests with clear therapeutic recommendations. Here we describe the Pharmacogenomics Appraisal, Evidence Scoring and Interpretation System (PhAESIS), developed as part of the Coriell Personalized Medicine Collaborative research study, and its application to seven commonly prescribed drugs.